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a  b  s  t  r  a  c  t
Our  understanding  of  female  reproductive  function  has  been  hampered  by  our  inability  to  directly  assess
the number  of  non-growing  primordial  follicles  present  in  the  ovary,  the  ovarian  reserve.  Female  repro-
ductive  hormones  (FSH  and  LH,  the  inhibins  and  steroids)  reﬂect  the  activity  of  the  larger  growing  follicles
and  thus  are  largely  informative  of  peri-ovulatory  ovarian  activity.  In  contrast  anti-Müllerian  hormone
(AMH)  is  a product  of  the  granulosa  cells  of small  growing  follicles,  whose  number  (and  therefore  circulat-
ing AMH  concentrations)  is  reﬂective  of the ovarian  reserve.  AMH  declines  with  age  in  adult  women,  and
emerging  data  suggest  a relationship  with  remaining  reproductive  lifespan  and  age  at the menopause.
Early  studies  demonstrated  that  AMH  concentrations  are  stable  across  the  menstrual  cycle,  adding  to  its
clinical  utility.  The  most  established  role  for AMH  measurement  is  in  women  about  to  start  IVF  treatment,
where  it is predictive  of  the  ovarian  response  and  is of clear  value  in identifying  women  at  risk  of  ovarian
hyperstimulation  syndrome  or  whose  response  will  be poor  and  thus  their  expectations  can  be tailored.
AMH  is  detectable  in  childhood,  and  although  relationships  to  puberty  are  not  yet available,  it  appears
that  AMH  rises  to  a peak  in  the  early  20s.  Developing  indications  include  in  assessment  and  individual-
isation  of  the  risk  to  fertility  from  chemotherapy,  in  the  diagnosis  of  PCOS  and  as a tumour  marker  in
granulosa  cell  tumours.  The  increasingly  routine  use  of  AMH  by  IVF  clinics  heralds  much  wider  adoption
in  a range  of  clinical  situations  across  the  reproductive  lifespan.
© 2011 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Our current understanding of female reproductive function
presumes that the ovary contains a ﬁnite number of oocytes
within primordial follicles, and that their depletion heralds the
menopause [1].  This pool of primordial follicles is formed dur-
ing fetal life from approximately 18 weeks gestation, following
oogonial proliferation, entry and arrest in meiosis, and interaction
with somatic cells. A small number of this resting pool of primor-
dial follicles is activated into growth every day throughout the
reproductive lifespan of a woman (including in childhood) with
the vast majority destined to undergo atresia [2].  Indeed before
puberty all growing follicles will become atretic, and after puberty
only one a month may  escape this fate and progress to ovula-
tion. The pool of resting follicles is the true ovarian reserve, but
the term ‘ovarian reserve’ is also widely used in the assisted con-
ception literature to mean the number of growing follicles that
can be recruited by exogenous FSH to grow to a pre-ovulatory
stage, resulting in the potential collection of an oocyte for assisted
reproduction. This growing pool is perhaps better termed the func-
tional ovarian reserve. Although the true and functional ovarian
reserves reﬂect different stages of follicular development, they
are inherently linked and both decline in parallel with increas-
ing age. Accurate measurement of the ovarian reserve has long
been a quest in reproductive medicine and recent years have
seen a dramatic increase in research in this ﬁeld, a large part of
which has been fuelled by the recognition that measurement of
anti-Müllerian hormone (AMH) in serum is a much more accu-
rate measure of the ovarian reserve than the other hormones that
have previously been available to us. Thus while inhibin B shows
good prediction of oocyte yield after superovulation [3],  it requires
measurement in the early follicular phase of the menstrual cycle
and only decreases late in the reproductive years [4].  It has there-
fore not supplanted FSH as the most widely used marker of the
ovarian reserve despite the latter hormone’s well-recognised lim-
itations.
AMH  was ﬁrst identiﬁed in the 1940s on the basis of its pro-
duction by the fetal Sertoli cell, resulting in loss of the Müllerian
duct system in the male. Production of AMH by granulosa cells
in the adult ovary was ﬁrst reported 30 years ago, in the chicken
[5], but research into its function and clinical utility only gathered
pace at the turn of the century with the development of commer-
cially available assays. Early studies demonstrated that serum AMH
showed a close correlation with the number of oocytes that were
obtained following superovulation for IVF [6],  and that it declined
with age in women [7,8]. These two ﬁndings are central to our cur-
rent understanding of the utility of AMH  as a measure of the ovarian
reserve.
In contrast to the large amount of clinical research on the util-
ity of measuring AMH, there are remarkably few data regarding its
biological functions. Early studies using an AMH knock-out mouse
demonstrated that perhaps its most important role is the regu-
lation of initiation of early follicle growth [9,10],  and subsequent
studies have indicated that it may  regulate the responsiveness of
growing follicles to FSH [11]. AMH  production by cumulus cells is
stimulated by the oocyte [12] consistent with additional functions
in mediating oocyte/cumulus maturation. In keeping with these
roles, AMH expression by granulosa cells of the follicle is initiated
at the onset of follicle growth, but equally importantly expression
then declines rapidly with little expression in antral follicles beyond
6–8 mm diameter in the human [13]. The lack of production of AMH
by the mural granulosa of larger follicles in the lead up to ovulation
(or by the corpus luteum) is critical for its clinical utility as it means
that its serum concentration varies little over the menstrual cycle
[14,15]. Thus for practical purposes it can be assayed at any stage
of the cycle.
Recognition of these unique characteristics has led to the rapid
adoption of AMH  for a range of indications. In this review we discuss
the potential uses and recent developments for AMH, and sum-
marise the evidence supporting its adoption into clinical practice.
1.1. Assessment of ovarian reserve before assisted conception
This is the most established indication for measuring AMH,
with many clinics now routinely assaying AMH  before IVF treat-
ment. As AMH  correlates strongly with the number of oocytes
obtained following superovulation, a baseline measurement allows
individualisation of both the treatment strategy and the patient’s
expectations [16,17].  Speciﬁcally women  with a high AMH  are
likely to respond excessively to exogenous gonadotrophins and
their treatment strategy can be modiﬁed to minimise the risk of
ovarian hyperstimulation syndrome (OHSS). Conversely women
with a low AMH  are likely to respond poorly to stimulation with
consequently a low chance of pregnancy, and their expectations can
be managed appropriately with alternatives like oocyte donation
discussed. Although AMH  is primarily a measure of oocyte quan-
tity rather than quality, it is positively associated with IVF live birth
rates independently of age [16,18,19].  This is primarily due to its
relationship with oocyte yield, as at any given age range women
with a higher AMH  are likely to have more oocytes retrieved and
thereby potentially more embryos for selection.
The cost-effectiveness of the use of an AMH-based treatment
strategy in IVF has recently been assessed, and proposed to lead
to substantial savings [20]. Some of this is through the more
accurate identiﬁcation of women at risk of OHSS who can then
be treated with a less intense stimulation regimen, with signiﬁ-
cant cost savings from fewer hospital admissions for OHSS. A less
patient-centred aspect of this analysis was however the exclusion
of women with a very low AMH  from state funded IVF, which
will inevitably result in exclusion of some women with a low-
but not zero-chance of success as there is no AMH  concentration,
even when it is undetectable, that is associated with absolutely no
chance of pregnancy.
1.2. Age-speciﬁc interpretation of AMH as a surrogate measure of
ovarian reserve
The production of AMH  by the growing follicle pool means that
its concentration varies across childhood, adolescence and adult
life [7,21].  Initial adult cohorts clearly demonstrated an age related
decline reaching undetectable levels in advance of the menopause
[22]. Subsequently AMH  nomograms have been reported and vali-
dated from very large cohorts of women  [23–25].  While these data
derive from women attending infertility clinics, subset analysis of
women  where there was  a severe male contribution to the infertil-
ity (and where female pathology is therefore less likely) showed no
difference from the whole cohort. Longitudinal data are lacking, but
the size of the cross-sectional cohorts now reported make it likely
that they will indeed reﬂect longitudinal changes at a population
level.
More recently AMH  concentrations in populations of children
and younger adults have been described, and a compilation of
these data now allows a description of AMH  concentration from
birth to the menopause (Fig. 1) [26]. This conﬁrms a transient
neonatal rise in AMH  similar to the well-described mini-puberty
of the male neonate, with a subsequent rise through childhood
and adolescence to a peak in the early 20s. Concentrations then
decline from the late 20s. Collectively these data indicate that AMH
shows no dramatic change at puberty but shows an increase from
late childhood through to early adulthood. These data are derived
from cross-sectional analyses and prospective multiple sampling
through puberty is required to test and reﬁne this model. The
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Fig. 1. Serum AMH  from conception to the menopause (note log scale). The red line is the peak model that best ﬁts the 3260 datapoints shown as triangles. The coefﬁcient
of  determination, r2, is 0.34, indicating that 34% of variation in serum AMH  levels is due to age alone. Peak serum AMH is at 24.5 years.
Reproduced from doi:10.1371/journal.pone.0022024.
continuing rise through later adolescence suggests that there are
ongoing changes in patterns of follicle maturation over perhaps a
decade following menarche.
These large studies also conﬁrm the wide variability in AMH
between women. This is in fact to be expected, as there is a com-
parably wide range in primordial and non-growing follicle number
[1,27],  and in age at menopause. The age-related changes in AMH
have also been modelled relative to the non-growing follicle (NGF)
pool [28]. During childhood the NGF pool shows an inverse rela-
tionship with AMH  (i.e. the former is declining while the latter is
rising), but both AMH and the rate of loss of the NGF pool (assumed
to reﬂect largely initiation of follicle growth) rise in parallel. After
a peak at age 24, both AMH  and NGF activation rate both start to
fall, mirroring the fall in non-growing follicle numbers.
1.3. Assessing and predicting gonadal damage
Our ability to interpret AMH  in an age-speciﬁc manner has
allowed the development of new applications. These include
accurate assessment of the impact of gonadotoxic therapy, e.g.
chemotherapy and radiotherapy, or of ovarian surgery, on the
ovarian reserve [29,30].  AMH  falls very rapidly with the onset of
chemotherapy [31,32].  In lymphoma analysis allowed the clear
demonstration of the toxicity of alkylating agent based therapy,
as those women showed little or no recovery of AMH  follow-
ing chemotherapy, whereas women receiving non-alkylating agent
therapy showed a good recovery to approximately pre-treatment
concentrations [32]. AMH  is also useful in prepubertal girls, show-
ing a fall during chemotherapy with recovery dependant on the
toxicity of the regimen used [33], while other reproductive hor-
mones are not of value in this context. Post-treatment follow-up
studies have also shown that AMH  concentrations are reduced
in women following treatment for cancer, either in childhood or
adulthood, with low AMH  concentrations most consistently seen
following total body radiation [31,34–37].  Normal concentrations
have also been reported in populations of women  following certain
chemotherapy regimens indicating that those particular thera-
pies do not cause loss of the ovarian reserve that is detectable
using this marker [37,38]. This essentially reassuring result in some
women  requires long term follow up with both fertility and age
of menopause as endpoints, and at present data with that degree
of completeness are lacking. The ability of the reproductive sys-
tem to compensate for rapid loss of follicle number is indicated by
the only modest change in reproductive lifespan following unilat-
eral oophorectomy [39]. If translatable to the post-chemotherapy
situation, this might indicate than only very substantial loss of
the ovarian reserve will have a clinically relevant impact. As AMH
reﬂects the number of growing follicles, small changes in the rate
of activation may  well not be detectable.
Comparable results have been reported following surgery for
ovarian endometriosis [30], with a fall in AMH  immediately fol-
lowing surgery, and recovery thereafter. Assuming that primordial
follicles cannot be replaced and that surgery (and chemother-
apy) removes both growing and non-growing follicles, this can
only indicate that a smaller non-growing pool re-establishes a
similar growing pool to that present pretreatment, thus normal-
ising AMH. It would appear, however, reasonable to reassure a
woman  regarding future fertility prospects if her AMH  is nor-
mal  following recovery from cancer or other treatments although
there is a lack of prospective data to substantiate this fully at
present.
A further consideration is whether a higher pre-treatment AMH
before chemotherapy makes it more likely that a woman will retain
ovarian function following treatment, whereas a women of the
same age but with a lower AMH  is more at risk of experiencing
a premature menopause. In support of this initial studies demon-
strated that pre-treatment AMH  was higher in women treated for
breast cancer who  retained menses 1 year after chemotherapy
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[40], and with higher post-treatment AMH  concentrations [41],
although others have found no difference [42]. A recent analysis
of menstrual and ovarian function 5 years after chemotherapy for
breast cancer found that pretreatment AMH  was indeed a predic-
tor of ongoing menses (with associated biochemical evidence of
increased ovarian activity) at that time [43]. Age was  also a predic-
tor, as expected, but strikingly in a multivariate analysis only AMH
remained predictive, with the effect of age no longer signiﬁcant.
This is consistent with age being a surrogate marker of the ovarian
reserve whose value becomes redundant when a direct marker of
adequate accuracy is included. This ﬁnding has since been repli-
cated in a preliminary report of a further small cohort [44], but
should also be replicated in younger cohorts of women with other
conditions, e.g. lymphoma, before this test can be recommended for
clinical practice. Furthermore it should be recognised that these
studies used ovarian function rather than fertility as an outcome
and while this is relevant for some long-term outcomes such as
osteoporosis and other risks of early ovarian insufﬁciency, for many
women the key question will be whether they will retain their
fertility after chemotherapy. Conﬁrmation that AMH provides indi-
vidualisation of risk can rapidly translate into clinical practice, with
more invasive or time-consuming methods of fertility preservation
being appropriate for women with a low AMH  whereas others with
a high AMH  may  elect to start treatment without delay.
1.4. Diagnosis in oligo/amenorrhea
Although we have classically measured gonadotrophins and
oestradiol to subclassify oligoamenorrhoa, a single AMH  measure-
ment may  be a better ﬁrst line investigation. In oligoamenorrhoeic
women with Polycystic Ovarian Syndrome (PCOS), AMH is often
dramatically high due to AMH  being produced by the large number
of antral follicles [45,46].  Conversely women with amenorrhoea
due to premature ovarian insufﬁciency have a low AMH, while
women with amenorrhea related to hyperprolactinemia or in
hypogonadotrophic hypogonadism often have normal circulating
concentrations of AMH  [47]. AMH  is also very high in women with
granulosa cell tumours, where it is of value as a tumour marker
[48].
Women  with hyperprolactinemia or hypogonadotrophic
hypogonadism will have low FSH concentrations and this might
therefore be expected to reduce AMH  production from the growing
follicle pool. However the degree of gonadotropin suppression
seems to be largely insufﬁcient to inﬂuence AMH production in
these two groups of women. Likewise AMH  production is reported
to be unaffected in women  taking the combined contraceptive
pill who also have signiﬁcant gonadotropin suppression [49],
although a rise in AMH  following discontinuation of the con-
traceptive pill has also been reported [50]. It appears that more
prolonged and complete gonadotropin suppression can cause
more readily detectable suppression of AMH, as seen in women
on long-term goserelin treatment for breast cancer [31], and this
may  also underpin the decline in AMH  concentrations during
pregnancy [51]. Clinical experience indicates that some women
with hypogonadotrophic hypogonadism do have a low AMH,
and further well-deﬁned cohorts of women with this condition
(including follow up to recovery of normal ovarian function) are
needed to delineate in detail possible changes in AMH. AMH
is thus far not part of the diagnostic work up for PCOS but the
criteria for making this diagnosis remains subject to revision and
it may  well be that AMH  becomes part of this in due course [52].
Certainly the markedly elevated AMH  concentrations contrast to
the frequently normal values of other reproductive hormones in
PCOS, thus raising the possibility of a clear biochemical aspect to
the diagnosis, which can also only aid further our understanding
of this condition.
1.5. Prediction of reproductive lifespan
The decline in AMH  during the later reproductive years is one
of the most established ﬁndings, in both prospective and cross-
sectional studies, thus raising the possibility of prediction of the
menopause [22] and by implication, a woman’s remaining repro-
ductive lifespan. In analysis of serial blood samples taken from 50
women  followed prospectively from the age of 42 it was  demon-
strated that AMH  declined to undetectable levels some 5 years
before the ﬁnal menstrual period (FMP) [53]. Inhibin B declined
similarly becoming undetectable some 4 years before the FMP.
AMH  was  signiﬁcantly related both to time to and age at FMP,
whereas inhibin B was  less predictive of both. A recent larger Dutch
study has provided further evidence that AMH  could provide long-
term prediction of age at menopause [54]. The study included 257
ovulatory women  aged 21–46, who  were reassessed after 11 years.
Analysis showed that a low age-speciﬁc AMH  at initial testing was
associated with a shift in the distribution of the menopause to a
younger age, whereas a higher age-speciﬁc AMH  shifted the dis-
tribution toward a higher age. Importantly in this study the use of
AMH  was in the context of age, rather than independent of it. Even
in this fairly large study however only some 11% of the women stud-
ied had become menopausal during the follow up period and thus
larger and longer duration studies will be required to provide accu-
rate estimates of the predictive power of AMH  and the variability
associated with this. It must be recognised that age at menopause is
very strongly genetically determined and although a large number
of environmental inﬂuences have been identiﬁed, their combined
effect is modest [55]. It will be interesting in future work to assess
whether AMH  is a better predictor than knowing the mothers’ age
at menopause.
2. Conclusion
The last decade has provided a wealth of data conﬁrming the
value of AMH  as a measure of the ovarian reserve. The clearest data
for its clinical utility is in the context of IVF and measurement has
been routine practice in some clinics now for several years. The
validity of the evidence base for other indications is weaker but
rapidly growing. Much of the value of AMH  lies in its relation to
the declining ovarian pool with age, and thus its potential ability to
predict future reproductive outcomes. We  must again emphasise
how little longitudinal or prospective data there are in this ﬁeld
and therefore its clinical use in advising individual women outside
the context of IVF is not well supported. The use of AMH  in women
with a new cancer diagnosis is promising as it may allow greater
individualisation of risk than is currently available, and its value
in the differential diagnosis of oligoamenorrhoea seems clear. It is
inevitable that AMH  will be increasingly measured by women wish-
ing to know their future reproductive lifespan, as societal changes
will continue to result in women  increasingly delaying childbearing
until their later reproductive years. This is likely to go hand in hand
with the more widespread use of fertility preservation technologies
such as oocyte vitriﬁcation for non-medical reasons despite the lack
of a clear evidence base. While bearing these caveats in mind it is
clear that the increasing use of AMH  will be of substantial beneﬁt
widely across reproductive medicine.
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